Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael A Posternak

Showing results (21-30 of 49) with videos related to

Pageof 5
Sort By:
The American Journal of Psychiatry|October 7, 2004
Using a self-report depression scale to identify remission in depressed outpatientsMark Zimmerman, Michael A Posternak, Iwona Chelminski
Journal of Clinical Psychopharmacology|March 2, 2005
Is it time to replace the Hamilton Depression Rating Scale as the primary outcome measure in treatment studies of depression?Mark Zimmerman, Michael A Posternak, Iwona Chelminski
The American Journal of Psychiatry|March 1, 2002
Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice?Mark Zimmerman, Jill I Mattia, Michael A Posternak
Psychiatric Services (Washington, D.C.)|March 5, 2002
Integrating outcomes research into clinical practiceMichael A Posternak, Mark Zimmerman, David A Solomon
The Journal of Clinical Psychiatry|November 2, 2005
Prevalence and features of intermittent explosive disorder in a clinical settingEmil F Coccaro, Michael A Posternak, Mark Zimmerman
Journal of Clinical Psychopharmacology|April 7, 2007
Impact of study design on the results of continuation studies of antidepressantsMark Zimmerman, Michael A Posternak, Camilo J Ruggero
The Journal of Clinical Psychiatry|February 13, 2002
An open-label study of citalopram in the treatment of pathological gamblingMark Zimmerman, Robert B Breen, Michael A Posternak
The Journal of Clinical Psychiatry|November 25, 2003
How many subjects with major depressive disorder meet eligibility requirements of an antidepressant efficacy trial?Gabor I Keitner, Michael A Posternak, Christine E Ryan
Depression and Anxiety|March 31, 2005
Standardized clinical outcome rating scale for depression for use in clinical practiceMark Zimmerman, Michael A Posternak, Iwona Chelminski, et al.
The Journal of Clinical Psychiatry|June 16, 2011
Response rates to fluoxetine in subjects who initially show no improvementMichael A Posternak, Lee Baer, Andrew A Nierenberg, et al.
Pageof 5

Showing results (21-30 of 49) with videos related to

Sort By:
Pageof 5
The American Journal of Psychiatry|October 7, 2004
Using a self-report depression scale to identify remission in depressed outpatientsMark Zimmerman, Michael A Posternak, Iwona Chelminski
Journal of Clinical Psychopharmacology|March 2, 2005
Is it time to replace the Hamilton Depression Rating Scale as the primary outcome measure in treatment studies of depression?Mark Zimmerman, Michael A Posternak, Iwona Chelminski
The American Journal of Psychiatry|March 1, 2002
Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice?Mark Zimmerman, Jill I Mattia, Michael A Posternak
Psychiatric Services (Washington, D.C.)|March 5, 2002
Integrating outcomes research into clinical practiceMichael A Posternak, Mark Zimmerman, David A Solomon
The Journal of Clinical Psychiatry|November 2, 2005
Prevalence and features of intermittent explosive disorder in a clinical settingEmil F Coccaro, Michael A Posternak, Mark Zimmerman
Journal of Clinical Psychopharmacology|April 7, 2007
Impact of study design on the results of continuation studies of antidepressantsMark Zimmerman, Michael A Posternak, Camilo J Ruggero
The Journal of Clinical Psychiatry|February 13, 2002
An open-label study of citalopram in the treatment of pathological gamblingMark Zimmerman, Robert B Breen, Michael A Posternak
The Journal of Clinical Psychiatry|November 25, 2003
How many subjects with major depressive disorder meet eligibility requirements of an antidepressant efficacy trial?Gabor I Keitner, Michael A Posternak, Christine E Ryan
Depression and Anxiety|March 31, 2005
Standardized clinical outcome rating scale for depression for use in clinical practiceMark Zimmerman, Michael A Posternak, Iwona Chelminski, et al.
The Journal of Clinical Psychiatry|June 16, 2011
Response rates to fluoxetine in subjects who initially show no improvementMichael A Posternak, Lee Baer, Andrew A Nierenberg, et al.
Pageof 5